CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338

Osteosarcoma (OS) is the most frequent primary malignant tumour of bone and metastases occur in 30% of cases, the 5-year survival rate is 25–30%. Although pre- and post-operative chemotherapy has improved prognosis in osteosarcoma (OS), high toxicity and natural and acquired drug-resistance are the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Bone Oncol
Hlavní autoři: Pollino, Serena, Palmerini, Emanuela, Dozza, Barbara, Bientinesi, Elisa, Piccinni-Leopardi, Martina, Lucarelli, Enrico, Righi, Alberto, Benassi, Maria Serena, Pazzaglia, Laura
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543022/
https://ncbi.nlm.nih.gov/pubmed/31193811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2019.100239
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky